Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held in San Diego and virtually November 1-5, 2023. Presentation Details Title: Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma Abstract Number: 321Date and Time: Friday, November 3rd : 12:00-1:30 p.m. and 5